News Antidepressants enhance DMT efficacy in patients with severe depression: Small Pharma study The study found that 100 per cent of patients were responsive and 92 per cent went into remission Natalia Buendia CalvilloSeptember 27, 2023
Psychedelics Billionaire Steve Cohen’s Point 72 hedge fund takes 8.1% stake in Cybin It now has 19 million shares of the psychedelic drug developer, the firm's first investment in a public entity of this variety Rowan DunneSeptember 19, 2023
Psychedelics Cybin inks agreement to acquire DMT drug developer Small Pharma The companies say they will have the most substantial dataset on the DMT molecule in the industry and largest IP portfolio Rowan DunneAugust 28, 2023
Psychedelics Small Pharma gets approval for upcoming injectable DMT trial on humans New phase I study will be held at MAC Clinical Research in Manchester, England next year Rowan DunneOctober 31, 2022
Psychedelics Small Pharma acquires U.S. patent for its DMT compounds The company has enhanced its IP portfolio with a patent that will be valid until 2041 Rowan DunneOctober 21, 2022